FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics. Modified release pharmaceutical composition is described. Composition contains 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazole-4-yl-ethinyl]-pyridine, speed-controlling polymer, and pH-dependent polymer. speed-controlling polymer is hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, or microcrystalline cellulose, and pH-dependent polymer is selected from group including ionic poly-(meth)-acrylates.
EFFECT: invention provides preparing dosage forms for sparingly soluble said active substance of modified release for reducing pH influence.
18 cl, 11 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| CONTROLLED-RELEASE COMPOSITIONS FOR ORAL USING | 2000 |
|
RU2281758C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| NEW PROLONGED COMPOSITIONS FOR PERORAL ADMINISTRATION | 1999 |
|
RU2286766C2 |
| METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| 2-CHLORO-4-[1-(4-FLUOROPHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHINYL]-PYRIDINE MONOSULPHATE SALT AND CRYSTALLINE FORM THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAID SALT AND PRODUCTION METHOD THEREOF | 2007 |
|
RU2460728C2 |
| PARKINSON'S DISEASE THERAPY USING COMBINATION WITH FIXED DOSAGES | 2013 |
|
RU2771522C2 |
| DRUG DELIVERY COMPOSITION | 2010 |
|
RU2589823C2 |
